Phase Ib trial to evaluate the tolerability and pharmacokinetics of neoadjuvant WX 671 in patients with head and neck cancer.

Trial Profile

Phase Ib trial to evaluate the tolerability and pharmacokinetics of neoadjuvant WX 671 in patients with head and neck cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Upamostat (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
    • 24 Sep 2007 Results have been reported.
    • 24 Sep 2007 Status changed from initiated to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top